[go: up one dir, main page]

DE69533067D1 - Hepatis e-virus antigene und dessen verwendungen - Google Patents

Hepatis e-virus antigene und dessen verwendungen

Info

Publication number
DE69533067D1
DE69533067D1 DE69533067T DE69533067T DE69533067D1 DE 69533067 D1 DE69533067 D1 DE 69533067D1 DE 69533067 T DE69533067 T DE 69533067T DE 69533067 T DE69533067 T DE 69533067T DE 69533067 D1 DE69533067 D1 DE 69533067D1
Authority
DE
Germany
Prior art keywords
hev
antigens
virus
useful
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69533067T
Other languages
English (en)
Other versions
DE69533067T2 (de
Inventor
R Fuerst
Patrick Mcatee
O Yarbough
Yi-Fan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genelabs Technologies Inc
Original Assignee
Genelabs Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Technologies Inc filed Critical Genelabs Technologies Inc
Publication of DE69533067D1 publication Critical patent/DE69533067D1/de
Application granted granted Critical
Publication of DE69533067T2 publication Critical patent/DE69533067T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28123—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
DE69533067T 1994-10-24 1995-10-23 Hepatis e-virus antigene und dessen verwendungen Expired - Lifetime DE69533067T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32795294A 1994-10-24 1994-10-24
US327952 1994-10-24
US08/542,634 US6214970B1 (en) 1988-06-17 1995-10-13 Hepatitis E virus antigens and uses therefor
US542634 1995-10-13
PCT/US1995/013703 WO1996012807A2 (en) 1994-10-24 1995-10-23 Hepatitis e virus antigens and uses therefor

Publications (2)

Publication Number Publication Date
DE69533067D1 true DE69533067D1 (de) 2004-06-24
DE69533067T2 DE69533067T2 (de) 2005-05-12

Family

ID=26986149

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69533067T Expired - Lifetime DE69533067T2 (de) 1994-10-24 1995-10-23 Hepatis e-virus antigene und dessen verwendungen

Country Status (8)

Country Link
US (2) US6214970B1 (de)
EP (1) EP0787190B1 (de)
JP (2) JPH10509588A (de)
AT (1) ATE267256T1 (de)
AU (1) AU4195696A (de)
DE (1) DE69533067T2 (de)
ES (1) ES2223054T3 (de)
WO (1) WO1996012807A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207416B1 (en) 1992-09-18 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
US6787145B1 (en) 1992-09-18 2004-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
DE69334299D1 (de) 1992-09-18 2009-12-31 Us Gov Health & Human Serv Rekombinante proteine eines pakistani stammes von hepatitis e-virus sowie ihre verwendung in diagnostischen verfahren und als vakzine
US6054567A (en) * 1997-04-11 2000-04-25 The United States Of America As Represented By The Department Of Health And Human Services Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
US6458562B1 (en) 1998-04-09 2002-10-01 The United States Of America As Represented By The Secretary Of Health And Human Services Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
CA2283538A1 (en) * 1999-09-30 2001-03-30 Mun Hon Ng New hev antigenic peptide and methods
CN101367869B (zh) 2000-09-30 2012-12-05 北京万泰生物药业股份有限公司 用于预防、诊断及治疗戊型肝炎病毒的多肽,及它们作为诊断试剂和疫苗
AU2003219760A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
JP2005102689A (ja) * 2003-09-08 2005-04-21 Mitsubishi Kagaku Bio-Clinical Laboratories Inc Ｅ型肝炎ウイルス様中空粒子
JP5869885B2 (ja) * 2009-02-27 2016-02-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｅ型肝炎ウイルス様粒子を用いた多抗原送達系
US8906863B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
US8906862B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Multiple antigen delivery system using hepatitis E virus-like particle
ES2928061T3 (es) * 2016-05-25 2022-11-15 Intervet Int Bv Vacuna contra el VHE
CN117083290A (zh) * 2021-03-26 2023-11-17 港大科桥有限公司 戊型肝炎病毒样颗粒及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455492B1 (en) 1988-06-17 2002-09-24 Genelabs Technologies, Inc. Hepatitis E virus vaccine and method
US5885768A (en) 1988-06-17 1999-03-23 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis E virus peptide antigen and antibodies
US5294548A (en) * 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
KR0178399B1 (ko) 1990-04-05 1999-04-01 프랭크 쿵 장을 통해 전염되는 비a비b형 간염 바이러스 병원체 및 그것의 특유한 에피토프
DE69334299D1 (de) 1992-09-18 2009-12-31 Us Gov Health & Human Serv Rekombinante proteine eines pakistani stammes von hepatitis e-virus sowie ihre verwendung in diagnostischen verfahren und als vakzine
ATE382696T1 (de) 1993-09-24 2008-01-15 Macfarlane Burnet Inst For Med Immunoreaktive antigene des hepatitis e viruses

Also Published As

Publication number Publication date
JP4237747B2 (ja) 2009-03-11
ATE267256T1 (de) 2004-06-15
ES2223054T3 (es) 2005-02-16
JP2006141400A (ja) 2006-06-08
WO1996012807A3 (en) 1996-05-30
AU4195696A (en) 1996-05-15
DE69533067T2 (de) 2005-05-12
WO1996012807A2 (en) 1996-05-02
JPH10509588A (ja) 1998-09-22
EP0787190A2 (de) 1997-08-06
US20020107360A1 (en) 2002-08-08
US6214970B1 (en) 2001-04-10
EP0787190B1 (de) 2004-05-19

Similar Documents

Publication Publication Date Title
DE69533067D1 (de) Hepatis e-virus antigene und dessen verwendungen
EP1200109A4 (de) Verwendung von peptid-nukleinsäureverbindungen zur auslösung zellulärer immunantworten gegen hepatitis c
DK1296711T3 (da) HPV-E7 til behandling af humant papillomavirus
AU2684792A (en) Porcine reproductive respiratory syndrome vaccine and diagnostic
CA2144855A1 (en) Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines
EA200300023A1 (ru) 3'-ПРОЛЕКАРСТВА 2'-ДЕЗОКСИ-β-L-НУКЛЕОЗИДОВ
AU7545801A (en) Chimeric human papillomavirus (hpv) l1 molecules and uses therefor
WO2001037869A9 (en) Vaccine compositions
WO2002022664A3 (en) Antigenic proteins of shrimp white spot syndrome virus and uses thereof
WO2007066188A3 (en) Marked bovine viral diarrhea virus vaccines
WO2002057314A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes
AU3830995A (en) Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines
CA2412075A1 (en) Attenuated bovine respiratory syncytial virus
ATE115964T1 (de) Non-a non-b sequenzen.
RU2313363C2 (ru) Очищенные белки оболочки вируса гепатита с для диагностического и терапевтического применения
WO1999024466A3 (en) Multi-mer peptides derived from hepatitis c virus envelope proteins for diagnostic use and vaccination purposes
RU2004104357A (ru) Вакцинный состав, потенцированный комбинацией днк и антигена
Inchauspe Protection and defence mechanisms in HCV infection
Berthold et al. Intrinsic interference caused by hepatitis sera
RU97117949A (ru) Аттенуированный штамм вируса заболевания свиней репродуктивным и респираторным синдромом (prrs), вакцина для защиты свиней от этого заболевания, клеточный клон почки обезьяны, способ получения аттенуированного штамма prrs-вируса, способ получения вакцины против prrs, способ диагностики prrs, способ обнаружения prrs-антител и применение аттенуированного вирусного штамма (варианты)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition